KURA ONCOLOGY INC (KURA) Stock Price, Quote, News and Overview
NASDAQ:KURA - Nasdaq - US50127T1097 - Common Stock - Currency: USD
KURA Quote, Performance and Key Statistics
5.76
-0.24 (-4%)
The current stock price of KURA is 5.76 USD. In the past month the price increased by 2.31%. In the past year, price decreased by -72.19%.
KURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Company Info
KURA ONCOLOGY INC
12730 High Bluff Drive, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 192
Phone: 18585008800
KURA ONCOLOGY INC / KURA FAQ
What is the stock price of KURA ONCOLOGY INC today?
The current stock price of KURA is 5.76 USD. The price decreased by -4% in the last trading session.
What is the ticker symbol for KURA ONCOLOGY INC stock?
The exchange symbol of KURA ONCOLOGY INC is KURA and it is listed on the Nasdaq exchange.
On which exchange is KURA stock listed?
KURA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KURA ONCOLOGY INC stock?
21 analysts have analysed KURA and the average price target is 26.78 USD. This implies a price increase of 364.84% is expected in the next year compared to the current price of 5.76. Check the KURA ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KURA ONCOLOGY INC worth?
KURA ONCOLOGY INC (KURA) has a market capitalization of 465.29M USD. This makes KURA a Small Cap stock.
How many employees does KURA ONCOLOGY INC have?
KURA ONCOLOGY INC (KURA) currently has 192 employees.
What are the support and resistance levels for KURA ONCOLOGY INC (KURA) stock?
KURA ONCOLOGY INC (KURA) has a support level at 5.61 and a resistance level at 6.17. Check the full technical report for a detailed analysis of KURA support and resistance levels.
Is KURA ONCOLOGY INC (KURA) expected to grow?
The Revenue of KURA ONCOLOGY INC (KURA) is expected to grow by 839.78% in the next year. Check the estimates tab for more information on the KURA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KURA ONCOLOGY INC (KURA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KURA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KURA, evaluating the profitability, health, valuation and growth aspects
- KURA ONCOLOGY INC (KURA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KURA ONCOLOGY INC (KURA) Sales and EPS estimates to see what analysts future expectations are.
- KURA ONCOLOGY INC (KURA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KURA ONCOLOGY INC (KURA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KURA ONCOLOGY INC (KURA) Stock Chart to make your own analysis
- KURA ONCOLOGY INC (KURA) Latest news and press-releases to stay up to date.
Does KURA ONCOLOGY INC (KURA) stock pay dividends?
KURA does not pay a dividend.
When does KURA ONCOLOGY INC (KURA) report earnings?
KURA ONCOLOGY INC (KURA) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of KURA ONCOLOGY INC (KURA)?
KURA ONCOLOGY INC (KURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
What is the Short Interest ratio of KURA ONCOLOGY INC (KURA) stock?
The outstanding short interest for KURA ONCOLOGY INC (KURA) is 11.12% of its float. Check the ownership tab for more information on the KURA short interest.
KURA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KURA. When comparing the yearly performance of all stocks, KURA is a bad performer in the overall market: 94.5% of all stocks are doing better.
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KURA. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 3.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.45% | ||
| ROE | -49.91% | ||
| Debt/Equity | 0.02 |
KURA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KURA. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of -9.19% and a revenue growth 839.78% for KURA